Join MAPS on LinkedIn to further build your professional connections within Medical Affairs through our Company and Group Pages.
Follow us on Twitter and say abreast of MAPS activities and key issues for Medical Affairs professionals.
Source: Stern AD, Alexander BM, Chandra A. How economics can shape precision medicines. Science 2017;355(6330):1131-1133. DOI:10.1126/science.aai8707
The emerging field of precision medicine—formerly known as personalized medicine—is taking the forefront in drug development. However, success in this arena will likely include moving away from the traditional model of drug development. Some of this is evidenced already as we see more companies engage in joint collaborations, such as Cota Healthcare and Novartis Pharmaceuticals working together to achieve improved clinical and cost outcomes for breast cancer patients.
An article published in the March 17, 2017, issue of Science examines the unique economics of precision medicines in the United States and reviews some of the factors that may impact their development, pricing, and access.
To access the full article, please visit the link below:
Please login or purchase a membership to view this content.